AZ Turnhout - Campus Sint-Elisabeth Trials

AZ Turnhout - Campus Sint-Elisabeth	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Trneny, Marek

BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

238

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

08/23

05/27

BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

250

Europe, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

05/25

08/26

ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL

Active, not recruiting

240

Europe, Canada, US, RoW

Brentuximab vedotin, Rituximab, Lenalidomide, Placebo

Seagen, a wholly owned subsidiary of Pfizer

Diffuse Large B-cell Lymphoma

05/25

04/27

BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting

Europe, US, RoW

brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone

Seagen, a wholly owned subsidiary of Pfizer

Peripheral T-cell Lymphoma

05/24

12/25

DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting

168

Europe, RoW

MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab

Miltenyi Biomedicine GmbH, ICON plc

Diffuse Large B-cell Lymphoma

01/25

07/29

EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting

180

Europe, Japan, US, RoW

Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®

Genmab, AbbVie

Diffuse Large B-Cell Lymphoma

01/26

07/27

NiHiL, NCT03199066: Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study

Recruiting

N/A

20000

RoW

Czech Lymphoma Study Group

Non Hodgkin Lymphoma (NHL)

12/20

12/27

Vrelust, Inge

EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting

180

Europe, Japan, US, RoW

Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®

Genmab, AbbVie

Diffuse Large B-Cell Lymphoma

01/26

07/27

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Trneny, Marek

Active, not recruiting

238

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

08/23

05/27

BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

250

Europe, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

05/25

08/26

ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL

Active, not recruiting

240

Europe, Canada, US, RoW

Brentuximab vedotin, Rituximab, Lenalidomide, Placebo

Seagen, a wholly owned subsidiary of Pfizer

Diffuse Large B-cell Lymphoma

05/25

04/27

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

650

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting

Europe, US, RoW

brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone

Seagen, a wholly owned subsidiary of Pfizer

Peripheral T-cell Lymphoma

05/24

12/25

DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting

168

Europe, RoW

MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab

Miltenyi Biomedicine GmbH, ICON plc

Diffuse Large B-cell Lymphoma

01/25

07/29

EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting

180

Europe, Japan, US, RoW

Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®

Genmab, AbbVie

Diffuse Large B-Cell Lymphoma

01/26

07/27

NiHiL, NCT03199066: Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study

Recruiting

N/A

20000

RoW

Czech Lymphoma Study Group

Non Hodgkin Lymphoma (NHL)

12/20

12/27

Vrelust, Inge

EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting

180

Europe, Japan, US, RoW

Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®

Genmab, AbbVie

Diffuse Large B-Cell Lymphoma

01/26

07/27



	Diseases Companies Products Productz Mechanisms of Action Sites